Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Aug 14, 2020; 26(30): 4479-4488
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4479
Table 1 Comparisons of deceased and surviving patients
ParameterAll patients (n = 412)Surviving patients (n = 335)Deceased patients (n = 77)P value
Age (yr)44.6 ± 10.643.9 ± 10.647.6 ± 10.20.007
Male, n (%)346 (84.0)279 (83.3)67 (87.0)0.421
Albumin (g/L)30.8 ± 12.330.5 ± 5.132.2 ± 6.70.587
Globulin (g/L)29.6 ± 9.029.7 ± 8.929.2 ± 9.40.624
Bilirubin (mg/dL)19.6 ± 7.919.0 ± 7.722.4 ± 8.10.001
ALT (U/L)145 (63-360)151 (63-353)183 (74-458)0.255
AST (U/L)153 (86-299)143 (85-285)189 (110-363)0.100
GGT (U/L)67 (40-101)69 (40-102)57 (39-94)0.226
Creatinine (μmol/L)74.2 ± 26.871.6 ± 21.785.1 ± 40.80.006
INR2.3 ± 0.62.7 ± 0.72.7 ± 0.7< 0.001
WBC (× 109/L)7.3 ± 3.37.0 ± 3.08.3 ± 4.10.015
Hemoglobin (g/L)115 ± 23117 ± 21111 ± 290.095
Platelet count (× 109/L)89 ± 4590 ± 4385 ± 530.367
HBV DNA (log10 IU/mL)3.1 ± 2.33.0 ± 2.33.3 ± 2.40.467
MELD24.4 ± 4.523.6 ± 4.227.8 ± 4.5< 0.001
HE, n (%)57 (13.9)37 (11.1)20 (26.7)< 0.001
UGB, n (%)11 (2.7)5 (1.5)6 (7.8)0.002
SBP, n (%)151 (37.0)125 (37.7)26 (34.2)0.575
Infection excluding SBP, n (%)184 (20.5)65 (19.5)19 (25.0)0.286
Hyponatremia, n (%)178 (43.8)138 (41.9)40 (51.9)0.151
Renal disfunction, n (%)215 (3.7)6 (1.8)9 (11.8)< 0.001
IL-6 (pg/mL)11.8 (5.4-25.9)10.4 (4.7-22.3)17.9 (7.3-57.6)0.011
Table 2 Comparisons of characteristics between patients with different levels of interleukin-6
ParameterHigh IL-6 level (n = 207)Low IL-6 level (n = 205)P value
Age (yr)44.8 ± 10.744.5 ± 10.50.777
Male, n (%)172 (83.1)174 (84.9)0.621
Albumin (g/L)29.6 ± 4.732.1 ± 16.80.039
Globulin (g/L)29.8 ± 9.329.5 ± 8.70.795
Bilirubin (mg/dL)20.0 ± 8.019.3 ± 7.80.362
ALT (U/L)119 (63, 333)178 (64, 433)0.070
AST (U/L)148 (84, 277)167 (92, 361)0.132
GGT (U/L)61 (38, 95)74 (42, 117)0.018
Creatinine (μmol/L)75.8 ± 28.872.5 ± 24.70.222
INR2.3 ± 0.62.3 ± 0.60.924
WBC (× 109/L)7.5 ± 3.67.0 ± 2.90.149
Hemoglobin (g/L)113 ± 23118 ± 230.036
Platelet count (× 109/L)89 ± 4990 ± 420.815
HBVDNA (log10 IU/mL)3.1 ± 2.43.1 ± 2.20.825
MELD24.7 ± 4.624.2 ± 4.40.241
HE, n (%)33 (16.1)24 (11.8)0.206
UGB, n (%)7 (3.4)4 (2.0)0.368
SBP, n (%)73 (35.8)78 (38.2)0.608
Infection excluding SBP, n (%)143 (21.0)41 (20.1)0.826
Hyponatremia, n (%)94 (43.8)90 (42.5)0.266
Renal disfunction, n (%)29 (4.4)6 (2.9)0.441
Mortality, n (%)50 (24.2)27 (13.2)0.004
Table 3 Risk factors associated with prognosis in hepatitis B virus-associated acute-on-chronic liver failure patients
ParameterFirst step
Last step
OR95%CIP valueOR95%CIP value
Age, per yr1.031.01-1.060.0081.041.01-1.070.009
Bilirubin, per 1 mg/dL1.051.02-1.090.0011.041.002-1.080.037
Albumin, per 1 g/L1.010.99-1.030.339---
Creatinine, per 1 μmol/L1.021.01-1.03< 0.0011.021.01-1.030.001
INR, per 1 unit3.462.27-5.28< 0.0013.542.19-5.72< 0.001
ALT, per 1 U/L1.001.00-1.000.197---
AST, per 1 U/L1.001.00-1.000.093---
GGT, per 1 U/L1.000.99-1.000.132---
Hemoglobin, per 1 g/L0.990.98-1.000.042---
HE (yes vs no1)2.921.58-5.400.0012.471.15-5.320.021
UGB (yes vs no1)5.541.65-18.670.0064.731.02-21.980.047
Hyponatremia (yes vs no1)1.370.99-1.900.057---
Renal disfunction (yes vs no1)27.342.53-21.32< 0.001---
IL-6, pg/ml (> 11.8 vs ≤ 11.81)2.101.26-3.510.0052.111.15-3.900.017
Table 4 Mortality between weeks 5 to 8 according to interleukin 6 levels at 4 wk
MortalityP valueHR (95%CI)P value
With low levels of IL-6 (n = 166)11 (6.6%)0.0351
With high levels of IL-6 (n = 80)12 (15.0%)2.39 (1.05-5.41)0.037
Table 5 Mortality according to the dynamic changes in interleukin-6 within 4 wk
MortalityHR (95%CI)P valueP value for trend
Group A (n = 60)3 (5.0%)10.023
Group B (n = 106)8 (7.5%)1.53 (0.41-5.78)0.528
Group C (n = 26)3 (11.5%)2.41 (0.49-12.0)0.281
Group D (n = 54)9 (16.7%)2.80 (0.72-10.83)0.136